SFX by Ex Libris Inc.

Title:	Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma
Source:	Science [0036-8075] Miao, D yr:2018

Basic

Sorry, no full text available...

Please use the document delivery service (see below)

Holding information

Holdings in library search engine ALBERT

Document delivery

Request document via Library/Bibliothek

Users interested in this article also expressed an interest in the following:
description	1.	Escudier, B. "Renal cell carcinoma." The Lancet 373.9669 (2009): 1119-32.
description	2.	Liu, D. "Toward Molecularly Driven Precision Medicine in Lung Adenocarcinoma." Cancer discovery 7.6 (2017): 555-557.
description	3.	Hamada, T. "Aspirin Use and Colorectal Cancer Survival According to Tumor CD274 (Programmed Cell Death 1 Ligand 1) Expression Status." Journal of clinical oncology 35.16 (2017): 1836-1844.
description	4.	Weber, Jeffrey S. "Sequential administration of nivolumab and ipilimumab with a planned switch in patients with advanced melanoma (CheckMate 064): an open-label, randomised, phase 2 trial." Lancet oncology 17.7 (2016): 943-955.
description	5.	Giannakis, M. "Genomic Correlates of Immune-Cell Infiltrates in Colorectal Carcinoma." Cell Reports 15.4 (2016): 857-865.
description	6.	Nanus, D M M. "Renal-cell carcinoma." New England Journal of Medicine, The 354.10 (1996): 865-75.
description	7.	Cairns, P. "Renal cell carcinoma." Cancer biomarkers 9.1 (2011): 461-473.
description	8.	Curti, Brendan D D. "Renal cell carcinoma." JAMA 292.1 (2004): 97-100.
description	9.	Seeliger, E. "Contrast-induced kidney injury: mechanisms, risk factors, and prevention." European heart journal 33.16 (2012): 2007-2015.
description	10.	Eggermont, V. "Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial." Lancet oncology 16.5 (2015): 522-30.
description	11.	Dou, R. "MicroRNA let-7, T Cells, and Patient Survival in Colorectal Cancer." Cancer immunology research 4.11 (2016): 927-935.
description	12.	Weber, Jeffrey S. "Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial." Lancet oncology 16.4 (2015): 375-84.
description	13.	Masugi, Y. "Tumour CD274 (PD-L1) expression and T cells in colorectal cancer." Gut 66.8 (2016): 1463-1473.
description	14.	Kosumi, K. "Tumor SQSTM1 (p62) expression and T cells in colorectal cancer." Oncoimmunology 6.ja (2017).
description	15.	Prall, F. "The PD-1 expressing immune phenotype of T cell exhaustion is prominent in the "immunoreactive" microenvironment of colorectal carcinoma." Histopathology 71.3 (2017): 366-374.
description	16.	Gotwals, P. "Prospects for combining targeted and conventional cancer therapy with immunotherapy." Nature Reviews. Cancer 17.5 (2017): 286-301.
description	17.	Lee, Michael S. "Right Versus Left Colon Cancer Biology: Integrating the Consensus Molecular Subtypes." Journal of the National Comprehensive Cancer Network 15.3 (2017): 411-419.
description	18.	Sloan, Emily A. "PD-L1 Expression in Mismatch Repair-deficient Endometrial Carcinomas, Including Lynch Syndrome-associated and MLH1 Promoter Hypermethylated Tumors." The American journal of surgical pathology 41.3 (2016): 326-333.
description	19.	Van-Allen, Diana M. "Genomic determinants of cancer immunotherapy." Current opinion in immunology 41 (2016): 32-38.
description	20.	Hamanishi, J. "Safety and Antitumor Activity of Anti-PD-1 Antibody, Nivolumab, in Patients With Platinum-Resistant Ovarian Cancer." Journal of clinical oncology 33.34 (2015): 4015-4022.